Table 2.
Clinical characteristics of 66 colorectal cancer patients.
| Characteristics | Number of patients (%) |
|---|---|
| Age (years), mean ± SD | 62 ± 12 |
| Gender | |
| Male | 42 (63.6) |
| Female | 24 (36.4) |
| ECOG performance status | |
| 0 | 35 (53) |
| 1 | 26 (39.4) |
| 2 | 5 (7.6) |
| Site of disease | |
| Rectum | 30 (45.5) |
| Sigmoid | 16 (24.2) |
| Right side | 8 (12.1) |
| Rectosigmoid | 5 (7.6) |
| Left side | 5 (7.6) |
| Transverse | 2 (3) |
| Sites of metastases | |
| Liver | 54 (59.4) |
| Lung | 31 (34) |
| Others | 6 (6.6) |
| Histopathology type | |
| Well differentiated | 16 (24.2) |
| Moderately differentiated | 49 (74.2) |
| Poorly differentiated | 1 (1.6) |
| Line of treatment | |
| First line | 11 (16.7) |
| Second line | 42 (63.6) |
| Third line | 13 (19.7) |
| Treatment regimen | |
| FOLFIRI | 28 (42.4) |
| Modified FOLFIRI | 18 (27.3) |
| Irinotecan | 8 (12.2) |
| FOLFIRI + cetuximab | 7 (10.6) |
| Irinotecan + capecitabine | 3 (4.5) |
| FOLFIRI + bevacizumab | 1 (1.5) |
| Irinotecan + cetuximab | 1 (1.5) |
ECOG Eastern Cooperative Oncology Group.